Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 10/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.51 |
| ▸ | CCR8 | P51685 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | HTR2B | P41595 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4275508 | 0.89 | KCNH2 (0.65) | SLC2A1KCNH2CCR8 | |
| SCHEMBL3770941 | 0.85 | KCNH2 (0.60) | SLC2A1KCNH2 | |
| SCHEMBL3781666 | 0.85 | SLC2A1 (0.53) | SLC2A1KCNH2 | |
| SCHEMBL3771607 | 0.84 | KCNH2 (0.57) | SLC2A1KCNH2 | |
| SCHEMBL3779184 | 0.83 | SLC2A1 (0.52) | SLC2A1KCNH2CCR8 | |
| SCHEMBL5777778 | 0.81 | SLC2A1 (0.47) | SLC2A1KCNH2HTR1ADRD2HTR2B | |
| SCHEMBL4708308 | 0.81 | KCNH2 (0.52) | SLC2A1KCNH2 | |
| SCHEMBL3774752 | 0.80 | KCNH2 (0.49) | SLC2A1KCNH2 | |
| SCHEMBL3779600 | 0.80 | KCNH2 (0.63) | SLC2A1KCNH2 | |
| SCHEMBL3775156 | 0.80 | KCNH2 (0.79) | SLC2A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324030-A1 | 5-Quinoline derivatives having an anti-bacterial activity | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2010-12-23 | — | — | US | disclosed |
| US-20100324030-A1 | 5-Quinoline derivatives having an anti-bacterial activity | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2010-12-23 | — | — | US | disclosed |
| US-20100324030-A1 | 5-Quinoline derivatives having an anti-bacterial activity | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2010-12-23 | — | — | US | disclosed |
| EP-1943222-A1 | ANTIBACTERIAL ACTIVE 5-CHINOLIN DERIVATIVE | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007042325-A1 | ANTIBACTERIAL ACTIVE 5-CHINOLIN DERIVATIVE | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324030-A1 | 5-Quinoline derivatives having an anti-bacterial activity | TOP2A, TOP1, TOP2B | SLC2A1 4605/4885KCNH2 3216/4885CCR8 4580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.